Profiles of inflammatory markers and lipoprotein subclasses in patients undergoing continuous ambulatory peritoneal dialysis

Clinica Chimica Acta

Volumn 411, Issue 21-22, 2010, Pages 1723-1727

  Kon, Mika ^a   Hirayama, Satoshi ^a   Horiuchi, Yuki ^a   Ueno, Tsuyoshi ^a   Idei, Mayumi ^a   Fueki, Yuriko ^b   Seino, Utako ^c   Goto, Shin ^c   Maruyama, Hiroki ^c   Iino, Noriaki ^c   Fukushima, Yoshifumi ^a   Ohmura, Hirotoshi ^a   Hirowatari, Yuji ^d   Miida, Takashi ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b International Welfare and Medical College   (Japan)

^c NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^d TOSOH CORPORATION   (Japan)

Author keywords

CAPD (continuous ambulatory peritoneal dialysis); ESRD (end stage renal disease); Hs CRP; IDL; LCAT; SAA

Indexed keywords

AMYLOID A PROTEIN; APOLIPOPROTEIN; C REACTIVE PROTEIN; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FAILURE; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; TREATMENT DURATION;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHOLESTEROL; DYSLIPIDEMIAS; FEMALE; HUMANS; INFLAMMATION; LIPOPROTEINS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY;

EID: 77956466500     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.07.016     Document Type: Article

References (24)

1. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
2. Cheung A.K., Sarnak M.J., Yan G., et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO study. Kidney Int 2004, 65:2380-2389.
3. Atkins R.C. The epidemiology of chronic kidney disease. Kidney Int Suppl 2005, 67(Suppl 94):S14-S18.
4. Nakai S., Masakane I., Akiba T., et al. Overview of regular dialysis treatment in Japan (as of 31 December 2005). Ther Apher Dial 2007, 11:411-441.
5. Bakris G.L., Ritz E. The message for World Kidney Day 2009. Hypertension and kidney disease: a marriage that should be prevented. Am J Nephrol 2009, 30:95-98.
6. Chmielewski M., Carrero J.J., Nordfors L., Lindholm B., Stenvinkel P. Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach. J Nephrol 2008, 21:635-644.
7. Filiopoulos V., Vlassopoulos D. Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes. Inflamm Allergy Drug Targets 2009, 8:369-382.
8. Little J., Phillips L., Russell L., Griffiths A., Russell G.I., Davies S.J. Longitudinal lipid profiles on CAPD: their relationship to weight gain, comorbidity, and dialysis factors. J Am Soc Nephrol 1998, 9:1931-1939.
9. Hirowatari Y., Yoshida H., Kurosawa H., Doumitu K.I., Tada N. Measurement of cholesterol of major serum lipoprotein classes by anion-exchange HPLC with perchlorate ion-containing eluent. J Lipid Res 2003, 44:1404-1412.
10. Hirowatari Y., Yoshida H., Fueki Y., et al. Measurement of cholesterol levels of major serum lipoprotein classes in hemodialysis patients by anion-exchange chromatography. Ann Clin Biochem 2008, 45:571-575.
11. Antunes A.A., Vannini F.D., Martin L.C., et al. Inflammation and overweight in peritoneal dialysis: is there an association?. Ren Fail 2009, 31:549-554.
12. Lin W., Chen Y.C., Wu M.S., et al. Icodextrin dialysate improves nutritional and inflammatory profiles in peritoneal dialysis patients. Ren Fail 2009, 31:98-105.
13. Shoji T., Ishimura E., Inaba M., Tabata T., Nishizawa Y. Atherogenic lipoproteins in end-stage renal disease. Am J Kidney 2001, 38:S30-S33.
14. Prasad N., Kumar S., Singh A., et al. Carotid intimal thickness and flow-mediated dilatation in diabetic and nondiabetic continuous ambulatory peritoneal dialysis patients. Perit Dial Int 2009, 29:S96-S101.
15. Attman P.O., Samuelsson O. Dyslipidemia of kidney disease. Curr Opin Lipidol 2009, 20(4):293-299.
16. Kawakami A., Yoshida M. Apolipoprotein CIII links dyslipidemia with atherosclerosis. J Atheroscler Thromb 2009, 16:6-11.
17. Babazono T., Nakamoto H., Kasai K., et al. Effects of icodextrin on glycemic and lipid profiles in diabetic patients undergoing peritoneal dialysis. Am J Nephrol 2007, 27:409-415. Japanese Extraneal Collaborated Study Group.
18. Jahangiri A. High-density lipoprotein and the acute phase response. Curr Opin Endocrinol Diabetes Obes 2010, 17:156-160.
19. von Eckardstein A. Differential diagnosis of familial high density lipoprotein deficiency syndromes. Atherosclerosis 2006, 186:231-239.
20. Chait A., Han C.Y., Oram J.F., Heinecke J.W. Thematic review series: the immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res 2005, 46:389-403.
21. Lowell C.A., Stearman R.S., Morrow J.F. Transcriptional regulation of serum amyloid A gene expression. J Biol Chem 1986, 261:8453-8461.
22. Coetzee G.A., Strachan A.F., van der Westhuyzen D.R., Hoppe H.C., Jeenah M.S., de Beer F.C. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition J Biol Chem 1986, 261:9644-9651.
23. Hoffman J.S., Benditt E.P. Changes in high density lipoprotein content following endotoxin administration in the mouse. Formation of serum amyloid protein-rich subfractions. J Biol Chem 1982, 257:10510-10517.
24. Miida T., Miyazaki O., Hanyu O., et al. LCAT-dependent conversion of preβ1-HDL into α-migrating HDL is severely delayed in hemodialysis patients. J Am Soc Nephrol 2003, 14:732-738.